UPMC receives $3.7 million PCORI award to improve care for patients with sepsis and pneumonia
February 19, 2020 08:00 ET
|
UPMC Health Plan
Pittsburgh, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Today the UPMC Center for High-Value Health Care, a nonprofit research organization housed within UPMC Insurance Services, announced it has been...
Amoxicillin Market To Reach USD 4,962.6 Million By 2026 | Reports And Data
November 04, 2019 11:42 ET
|
Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Government initiatives for the reach of amoxicillin for treating children with bacterial pneumonia, collaborations for technical advancements, and...
BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman
October 22, 2019 16:53 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur....
BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia"
August 22, 2019 10:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing technology to control inflammation while protecting immune function and vital...
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
August 07, 2019 10:00 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
February 07, 2019 09:18 ET
|
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Vystar Debuts Enhanced RxAir® UV Light Air Purifiers to Fight Flu, Colds & Airborne Germs
January 28, 2019 09:37 ET
|
Vystar Corp
Features longer-lasting, more effective UV light for more efficient inactivation of viruses and bacteriaRxAir available for medical, business and residentialRxAir now available via Vystar’s medical...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 06:45 ET
|
Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
December 12, 2016 09:01 ET
|
Cempra, Inc.
—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...